"Obi Reborn" Art

( Kensei Takeda ) 복식문화학회 2003 워크샵 Vol.2003 No.-

In addition to the known and intended use of Japanese "obi" as a sash to the traditional kimono outfit, it has been used for years as a decorative accessory to interior design. They are often seen as tapestries hung on walls, runners on tables and dressers and sometimes are used in the recreation and design of clothing. Several years ago, as a result of his lifelong interest in art, both western and Asian, Mr. Takeda decided to give a rebirth to antique obi which otherwise might not have been used again. Oftentimes, obi cannot be used as a result of wear or soiling to the material. However, due to the extreme length of the article, there are nearly always sections of obi which can be salvaged and given new life. This has been the challenge of Mr. Takeda, and he has created vibrant framed art using obi, obi ties ("obijime") and kimono material as the main media for this unique type of art. In this presentation, several examples of orginal antique obi were presented to the participants and the finished art works were then shown to demonstrate how the obi and accessories were assembled, painted, matted and framed to bring about the finished pieces. Depending on the artists location, one of the most difficult tasks in preparing to create these works is the actual finding of the antique obi. They can usually be found in Japanese antique shops or used kimono shops. Furthermore, the artist must be able to look at various obi, kimono and accessories and visualize the artistic layout possible with the materials at hand. Obviously, all antique obi and related material do not lend themselves to being paired with other material, and in many cases the condition of the material must be carefully inspected. Silk becomes very delicate with age, and antique obi can easily tear or even disintegrate when washed and stretched. In some cases, only trial and error will determine if a particular piece of material can be used in this manner. Although it was not feasible to demonstrate the washing, drying pressing, stretching and mounting of the obi at this particular demonstration, the procedure was described. An orginal obi was presented to the audience in it``s state before the above-mentioned steps. Then, a mounted portion of the same obi was offered as a working sample. Mr. Takeda uses acrylic and water colors, usually straight from the tube and undiluted, as his paint media. A short demonstration of the painting technique was demonstrated. The traditional wearing of kimono is a harmony of pattern, color, texture and layering of material. Mr. Takeda keeps this same concept in his art. Very old Japanese art tends to be flat, but he strives to bring about dimension to the materials in his finished art work. At the same time, Mr. Takeda always respects the work of the original artist while creating his own image. Depending on the theme of the work, he occasionally uses other materials such as beads, and in some instances, antique pieces of jewelry. In this way, each wark takes on a truly three-dimensional form. The choice of his frames is influenced by the environment in which the art is to be displayed. Although the initial materials are of Japanese origin, the frames reflect the interior design of the environment in which the art is to be shown. Also, both the frames and the mats are partially chosen based on the theme or title of the finished work. Mr. Takeda``s final works of art are a result of not only painting, but also manipulation and co-ordination of various materials related to kimono. It was a result of his long-time appreciation of traditional kimono and obi that he started to use these materials in his art. In this way, he has created objects of art which allow viewers to enjoy these traditional materials in everyday life.

Development of Heat Absorbing and High Electromagnetic Shielding Pre-Painted Steel Sheet

( Tomoaki Hosokawa ),( Kohei Ueda ),( Kensei Yuasa ),( Makoto Nakazawa ) 한국부식방식학회(구 한국부식학회) 2010 Corrosion Science and Technology Vol.9 No.4

Carcinogenic Role of Tumor Necrosis Factor-α Inducing Protein of Helicobacter pylori in Human Stomach

Masami Suganuma,Takashi Kuzuhara,Kensei Yamaguchi,Hirota Fujiki 한국생활환경학회 2006 BMB Reports Vol.39 No.1

Carcinogenic Role of Tumor Necrosis Factor-α Inducing Protein of Helicobacter pylori in Human Stomach

Suganuma, Masami,Kuzuhara, Takashi,Yamaguchi, Kensei,Fujiki, Hirota Korean Society for Biochemistry and Molecular Biol 2006 Journal of biochemistry and molecular biology Vol.39 No.1

Helicobacter pylori is the definitive carcinogen for stomach cancer and is known to induce proinflammatory cytokines, such as tumor necrosis factor-$\alpha$ (TNF-$\alpha$) and interleukin-1(IL-1) in the stomach. Based on our findings that TNF-$\alpha$ is an endogenous tumor promoter, we identified the TNF-$\alpha$ inducing protein (Tip$\alpha$) gene family, and confirmed Tip$\alpha$ and HP-MP1 as new carcinogenic proteins of H. pylori. Tip$\alpha$ protein is unique to H. pylori, and this paper shows the strong tumor promoting activity of Tip$\alpha$ gene family, in cooperation with Ras protein and its mechanisms of action in relation to NF-${\kappa}B$ activation, and discusses the carcinogenic role of Tip$\alpha$ in stomach cancer. Our recent finding showing that penicillin-binding proteins of other bacteria are weak homologues of Tip$\alpha$ is also discussed.

Carcinogenic Role of Tumor Necrosis Factor-α Inducing Protein ofHelicobacter pylori in Human Stomach

Hirota Fujiki,Masami Suganuma,Takashi Kuzuhara,Kensei Yamaguchi 한국생화학분자생물학회 2006 BMB Reports Vol.39 No.1

Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW Study

Kei Muro,Takatsugu Ogata,Yukiya Narita,Zev A. Wainberg,Eric Van Cutsem,Kensei Yamaguchi,Yongzhe Piao,Yumin Zhao,Patrick M. Peterson,Sameera R. Wijayawardana,Paolo Abada,Anindya Chatterjee 대한위암학회 2023 Journal of gastric cancer Vol.23 No.2

Purpose: Liver metastasis (LM) is reported in approximately 40% of patients with advanced/metastatic gastric/gastroesophageal junction adenocarcinoma (metastatic esophagogastric adenocarcinoma; mGEA) and is associated with a worse prognosis. This post-hoc analysis from the RAINBOW trial reported the efficacy, safety, and biomarker outcomes of ramucirumab and paclitaxel combination treatment (RAM+PAC) in patients with (LM+) and without (LM−) LM at baseline. Materials and Methods: Patients (n=665) were randomly assigned on a 1:1 basis to receive either RAM+PAC (LM+: 150, LM−: 180) or placebo and paclitaxel (PL+PAC) (LM+: 138, LM−: 197). The overall survival (OS) and progression-free survival (PFS) were evaluated using stratified Kaplan–Meier and Cox regression models. The correlation of dichotomized biomarkers (VEGF-C, D; VEGFR-1,2) with efficacy in the LM+ versus LM− subgroups was analyzed using the Cox regression model with reported interaction P-values. Results: The presence of LM was associated with earlier progression than those without LM, particularly in patients receiving PL+PAC (hazard ratio [HR], 1.68). RAM+PAC treatment improved OS and PFS irrespective of LM status but showed greater improvement in LM+ than that in LM− (OS HR, 0.71 [LM+] vs. 0.88 [LM−]; PFS HR, 0.47 [LM+] vs. 0.76 [LM−]). Treatment-emergent adverse events were similar between patients with and without LM. No predictive relationship was observed between biomarker levels (VEGF-C, D; VEGFR-1,2) and efficacy outcome (OS, PFS) (all interaction P-values >0.05). Conclusions: RAM provided a significant benefit, irrespective of LM status; however, its effect was numerically stronger in patients with LM. Therefore, RAM+PAC is a clinically meaningful therapeutic option for patients with mGEA and LM.

Efficacy of endoscopy under general anesthesia for the detection of synchronous lesions in oro-hypopharyngeal cancer

Yoichiro Ono,Kenshi Yao,Yasuhiro Takaki,Satoshi Ishikawa,Kentaro Imamura,Akihiro Koga,Kensei Ohtsu,Takao Kanemitsu,Masaki Miyaoka,Takashi Hisabe,Toshiharu Ueki,Atsuko Ota,Hiroshi Tanabe,Seiji Haraoka 대한소화기내시경학회 2023 Clinical Endoscopy Vol.56 No.3

Background/Aims: Image-enhanced endoscopy can detect superficial oro-hypopharyngeal squamous cell carcinoma; however, reliable endoscopy of the pharyngeal region is challenging. Endoscopy under general anesthesia during transoral surgery occasionally reveals multiple synchronous lesions that remained undetected on preoperative endoscopy. Therefore, we aimed to determine the lesion detection capability of endoscopy under general anesthesia for superficial oro-hypopharyngeal squamous cell carcinoma. Methods: This retrospective study included 63 patients who underwent transoral surgery for superficial oropharyngeal squamous cell carcinoma between April 2005 and December 2020. The primary endpoint was to compare the lesion detection capabilities of preoperative endoscopy and endoscopy under general anesthesia. Other endpoints included the comparison of clinicopathological findings between lesions detected using preoperative endoscopy and those newly detected using endoscopy under general anesthesia. Results: Fifty-eight patients (85 lesions) were analyzed. The mean number of lesions per patient detected was 1.17 for preoperative endoscopy and 1.47 for endoscopy under general anesthesia. Endoscopy under general anesthesia helped detect more lesions than preoperative endoscopy did (p<0.001). The lesions that were newly detected on endoscopy under general anesthesia were small and characterized by few changes in color and surface ruggedness. Conclusions: Endoscopy under general anesthesia for superficial squamous cell carcinoma is helpful for detecting multiple synchronous lesions.

Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer

Bang, Yung-Jue,Cho, Jae Yong,Kim, Yeul Hong,Kim, Jin Won,Di Bartolomeo, Maria,Ajani, Jaffer A.,Yamaguchi, Kensei,Balogh, Agnes,Sanchez, Teresa,Moehler, Markus American Association for Cancer Research 2017 Clinical Cancer Research Vol.23 No.19

<P><B>Purpose:</B> Ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte–associated protein-4 interactions, enhances T-cell activation and promotes tumor immunity. This phase II study evaluated the safety and efficacy of ipilimumab monotherapy versus best supportive care (BSC) among patients with advanced/metastatic gastric or gastroesophageal junction cancer who achieved at least stable disease with first-line chemotherapy.</P><P><B>Experimental Design:</B> Eligible patients were randomized to ipilimumab 10 mg/kg every 3 weeks for four doses, then 10 mg/kg every 12 weeks for up to 3 years, or BSC, which could include continuation of fluoropyrimidine until progression or toxicity. The primary endpoint was immune-related progression-free survival (irPFS); secondary endpoints included PFS by modified World Health Organization criteria and overall survival (OS).</P><P><B>Results:</B> Of 143 patients screened, 57 were randomized to each arm. irPFS with ipilimumab versus BSC was not improved [2.92 months, 95% confidence interval (CI), 1.61–5.16 vs. 4.90 months, 95% CI, 3.45–6.54, HR = 1.44; 80% CI, 1.09–1.91; <I>P</I> = 0.097], resulting in study cessation. At study closeout, which occurred 8 months after the interim analysis, the median OS durations were 12.7 months (95% CI, 10.5–18.9) and 12.1 months (95% CI, 9.3–not estimable), respectively. Grade 3/4 treatment-related adverse events occurred in 23% of ipilimumab-treated patients, in whom diarrhea (9%) and fatigue (5%) were most frequent, and in 9% of active BSC-treated patients.</P><P><B>Conclusions:</B> Although ipilimumab at 10 mg/kg was manageable, it did not improve irPFS versus BSC. However, comparable median OS of approximately 1 year and a favorable safety profile support the investigation of ipilimumab in combination with other therapies for advanced gastric cancer. <I>Clin Cancer Res; 23(19); 5671–8. ©2017 AACR</I>.</P>

Association between occurrence of multiple white and flat elevated gastric lesions and oral proton pump inhibitor intake

Rino Hasegawa,Kenshi Yao,Takao Kanemitsu,Hisatomi Arima,Takayuki Hirase,Yuuya Hiratsuka,Kazuhiro Takeda,Kentaro Imamura,Kensei Ohtsu,Yoichiro Ono,Masaki Miyaoka,Takashi Hisabe,Toshiharu Ueki,Hiroshi T 대한소화기내시경학회 2024 Clinical Endoscopy Vol.57 No.1

Background/Aims: Multiple white and flat elevated lesions (MWFL) that develop from the gastric corpus to the fornix may be strongly associated with oral antacid intake. Therefore, this study aimed to determine the association between the occurrence of MWFL and oral proton pump inhibitor (PPI) intake and clarify the endoscopic and clinicopathological characteristics of MWFL. Methods: The study included 163 patients. The history of oral drug intake was collected, and serum gastrin levels and anti-Helicobacter pylori immunoglobulin G antibody titers were measured. Upper gastrointestinal endoscopy was performed. The primary study endpoint was the association between MWFL and oral PPI intake. Results: In the univariate analyses, MWFL were observed in 35 (49.3%) of 71 patients who received oral PPIs and 10 (10.9%) of 92 patients who did not receive oral PPIs. The occurrence of MWFL was significantly higher among patients who received PPIs than in those who did not (p<0.001). Moreover, the occurrence of MWFL was significantly higher in patients with hypergastrinemia (p=0.005). In the multivariate analyses, oral PPI intake was the only significant independent factor associated with the presence of MWFL (p=0.001; odds ratio, 5.78; 95% confidence interval, 2.06–16.2). Conclusions: Our findings suggest that oral PPI intake is associated with the presence of MWFL (UMINCTR 000030144).

Efficacy and Safety of Trastuzumab Deruxtecan and Nivolumab as Third- or Later-Line Treatment for HER2-Positive Advanced Gastric Cancer: A Single-Institution Retrospective Study

Daisuke Takahari,Keitaro Shimozaki,Izuma Nakayama,Kengo Nagashima,Koichiro Yoshino,Koshiro Fukuda,Shota Fukuoka,Hiroki Osumi,Mariko Ogura,Takeru Wakatsuki,Akira Ooki,Eiji Shinozaki,Keisho Chin,Kensei 대한위암학회 2023 Journal of gastric cancer Vol.23 No.4

Purpose: Determination of optimal treatment strategies for HER2-positive advanced gastric cancer (AGC) in randomized trials is necessary despite difficulties in direct comparison between trastuzumab deruxtecan (T-DXd) and nivolumab as third or later-line treatments. Materials and Methods: This single-institution, retrospective study aimed to describe the real-world efficacy and safety of T-DXd and nivolumab as ≥ third line treatments for HER2-positive AGC between March 2016 and May 2022. Overall, 58 patients (median age, 64 years; 69% male) were eligible for the study (T-DXd group, n=20; nivolumab group, n=38). Results: Most patients exhibited a HER2 3+ status (72%) and presented metastatic disease at diagnosis (66%). The response rates of 41 patients with measurable lesions in the T-DXd and nivolumab groups were 50% and 15%, respectively. The T-DXd and nivolumab groups had a median progression-free survival of 4.8 months (95% confidence interval [CI], 3.3, 7.0) and 2.3 months (95% CI, 1.5, 3.5), median overall survival (OS) of 10.8 months (95% CI, 6.9, 23.8) and 11.7 months (95% CI, 7.6, 17.1), and grade 3 or greater adverse event rates of 50% and 2%, respectively. Overall, 64% patients received subsequent treatment. Among 23 patients who received both regimens, the T-DXd–nivolumab and nivolumab–T-DXd groups had a median OS of 14.0 months (95% CI, 5.0, not reached) and 19.3 months (95% CI, 9.5, 25.1), respectively. Conclusions: T-DXd and nivolumab showed distinct efficacy and toxicity profiles as ≥ third line treatments for HER2-positive AGC. Considering the distinct features of each regimen, they may help clinicians personalize optimal treatment approaches for these patients.